癲癇市場：KOL 洞察

本報告考察了全球癲癇市場並提供了市場概述，包括批准的治療方法、管道趨勢和未來前景。

目錄

執行摘要

癲癇的未來治療範例

研究目的

鈉通道阻斷劑

• 非處方療法
  • 卡馬西平相關抗癲癇藥物
  • Vinpat（拉科醯胺、UCB）
  • Xcopri/Ontozry（cenobamate，SK Life Science）

神經調節劑

• 非處方療法
  • Briviat（布瓦西坦，UCB）

GABA能機制

• 非處方療法
  • 苯並二平（救援藥物）
  • Tutalmy（加奈索酮，Marinus Pharmaceuticals）

其他作用機轉

• 非處方療法
  • Epidiolex/Epidyolex（大麻二酚，Jazz Pharmaceuticals）
  • Fintepra（芬氟拉明，UCB）
  • Fycompa（□崙帕奈、衛材）

遲到的產品

• 管道處理
  • Belviq（氯卡色林、衛材）
  • Soticlestat（武田）
  • Karizba Mate（SK 生命科學）

早期產品

• 管道處理
  • ACT-709478/NBI-827104（神經分泌生物科學）
  • XEN1101（Xenon Pharmaceuticals）
  • 克立咪唑（EPX-100，Epygenix Therapeutics）

未來的治療範例

附錄

KOLs see the potential in Marinus Pharmaceuticals' Ztalmy for treating Lennox-Gastaut syndrome, but in what other setting do they perceive it might provide value, and what factors could limit its uptake? Experts accept that Eisai's Fycompa is an effective treatment for both focal and generalized epilepsies, but what safety concerns do they express? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to KOL Bulletins.

Table of Contents

Executive summary (11)

Future treatment paradigm for epilepsy

Research objectives (1)

Sodium channel blockers (20)

• Marketed therapies (20)
  • Carbamazepine-related anti-seizure drugs (5)
  • Vimpat (lacosamide; UCB) (6)
  • Xcopri/Ontozry (cenobamate; SK Life Science) (9)

Neuromodulators (5)

• Marketed therapies (5)
  • Briviact (brivaracetam; UCB) (5)

GABAergic mechanisms (20)

• Marketed therapies (20)
  • Benzodiapines (rescue medications) (8)
  • Ztalmy (ganaxolone; Marinus Pharmaceuticals) (12)

Other modes of action (24)

• Marketed therapies (24)
  • Epidiolex/Epidyolex (cannabidiol; Jazz Pharmaceuticals) (8)
  • Fintepla (fenfluramine; UCB) (6)
  • Fycompa (perampanel; Eisai) (10)

Late-stage products (31)

• Pipeline therapies (31)
  • Belviq (lorcaserin; Eisai) (14)
  • Soticlestat (Takeda) (10)
  • Carisbamate (SK Life Science) (7)

Early-stage products (17)

• Pipeline therapies (17)
  • ACT-709478/NBI-827104 (Neurocrine Biosciences) (5)
  • XEN1101 (Xenon Pharmaceuticals) (7)
  • Clemizole (EPX-100; Epygenix Therapeutics) (5)

Future treatment paradigm (9)

Appendix (3)

• KOL details (3)
  • US KOLs (1)
  • European KOLs (1)